Real-World Impact Assessment

At ISPOR 2026, we presented posters addressing outcomes in relapsed/refractory DLBCL, and introducing a reproducible method for generating population estimates robust enough to stand up in HTA and regulatory submissions.

We are honored to share that TriNetX has won the “Clinical Trial Innovation Award” in the 10th annual MedTech Breakthrough Awards.

Clinical development costs now average roughly $708 million per approved therapy. The industry’s need for accessible and trustworthy insight from real‑world data has never been greater.

We spotlight Tasfia’s work at Penn State and distilling practical lessons for other researchers navigating the complexities of cohort-based RWE studies.

Discover how real-world evidence untaps the potential of perioperative systemic therapy in muscle-invasive bladder cancer (MIBC) care.

In our latest Inside the Trends vodcast episode, COO Steve Kundrot spoke with Dr. Sarju Ganatra , a cardiologist and Co-Director of the Lahey Innovation Hub. They stripped patient-centricity back to its core.

TriNetX is proud to announce that we were named a Best of Show Finalist at SCOPE, the summit for clinical ops executives, one of the industry’s premier events focused on advancing clinical operations and innovation.

As we step into 2026, explore the resources that captivated our community in 2025, and more importantly, why they mattered.

In the 2025 TriNetX and studioID survey of 150 senior biopharma executives, all participants agreed that real-world evidence has the potential to improve regulatory submissions, underscoring the urgency for sponsors to integrate RWE more strategically into their regulatory playbooks.

As 2025 wraps up, the TriNetX team is reflecting on a year of milestones, among them, being named to The Healthcare Technology Report’s Top 50 Healthcare Technology Companies list this November.

Chimeric antigen receptor (CAR) T-cell therapy is among the most promising breakthroughs in modern oncology. By genetically engineering a patient’s T lymphocytes to recognize and destroy cancer cells, CAR T-cell therapy has redefined what is possible in adoptive cellular immunotherapy.

To succeed, biotechs are rethinking how clinical research gets done. RWD, AI, and patient-centric strategies are no longer experimental; they’re emerging as the core toolkit for companies determined to accelerate progress while controlling risk.

The recent ISPOR Europe 2025 conference, held under the inspiring theme ‘Powering Value and Access Through Patient-Centered Collaboration

I recently had the opportunity to sit down with Danny Levine for an episode of his RARECast podcast  to discuss something I’m deeply passionate about: how real-world data (RWD) is transforming the landscape of rare disease research.

At the recent SCOPE Europe conference, I spoke about a fundamental shift redefining the future of clinical research.

When we think about the future of clinical research, it’s easy to picture gleaming technology, seamless data flows, and a world where trials are faster, smarter, and more inclusive. But let’s be honest. We’re not there yet. 

We’re proud to announce that our TriNetX LIVE™ platform was recognized as a Best of Show Finalist at the SCOPE Europe conference.

Discover why TriNetX is the most-cited EHR dataset in peer-reviewed publications. Explore how our high-quality real-world data (RWD) powers high-impact research in top-tier medical journals and drives global breakthroughs in real-world evidence.

Clinical trials are the cornerstone of medical advancements, playing a pivotal role in the development of new treatments, interventions and understanding of diseases.

In my role at TriNetX, I have the privilege of engaging with leaders across the clinical research landscape who are challenging the status quo and pushing us toward a more inclusive, tech-enabled, and patient-first future.

As clinical trials evolve, one thing is certain: representativeness is no longer a nice-to-have; it’s a non-negotiable. The data are clear. In the 2025 TriNetX and studioID survey of 150 senior biopharma executives, 84% reported ramping up efforts to improve representativeness and accessibility in clinical research over the past few years.

Reflecting on the discussions from this year’s International Society for Pharmacoepidemiology (ISPE) Annual Meeting and looking ahead to the future of the field, I’m struck by the steady but significant evolution pharmacoepidemiology is undergoing driven in large part by innovations in real-world data (RWD).

In just a few years, real-world data (RWD) has evolved from an industry buzzword to a core driver of progress in drug development. What used to be experimental is now operational and increasingly essential. In the 2025 TriNetX and studioID survey of 150 senior biopharma executives, more than three-quarters said their organizations are already applying RWD across some part of the drug development lifecycle. We’re clearly well beyond the pilot phase.

Clinical trials often falter at the final stretch—when it’s time to execute. It’s here that well-intentioned protocols meet real-world complexity, where timelines can slip, costs may surge, and outcomes could fall short of expectations.

In the high-stakes world of clinical research, innovation doesn’t just happen in the lab; it must cross the clinical trial finish line of regulatory submission. Yet for many sponsors, sites, and researchers, patient recruitment—or the “last mile”—remains a costly bottleneck where recruitment can lag, site enrollment can underperform, and promising treatments never receive approval.

Fresh from the dynamic and idea-rich environment of ISPOR 2025, the premier global conference on health economics and outcomes research (HEOR), one message emerged loud and clear: innovation is rapidly reshaping the HEOR landscape, yet foundational challenges remain that require renewed attention and action. 

Clinical trials are being reinvented by real-world data (RWD). In 2025, data-driven strategies won’t just complement trial design—they’ll define it. From protocol optimization to accelerated site identification, data is the new compass guiding clinical innovation

The result? Higher costs, longer timelines, and compromised outcomes. The need to solve these critical challenges has never been more urgent.

With Robert F. Kennedy Jr. now at the helm of the Department of Health and Human Services (HHS), his recent speech to agency staff marked the beginning of what could be a seismic shift in U.S. healthcare policy. Among his key initiatives: launching investigations into whether antidepressants and the childhood vaccine schedule are contributing to chronic diseases. 

Combining disparate data sources to inform clinical trial site selection has long been a complex challenge. Inconsistent site naming, differences in the definition of a site, and a lack of potential patient counts, among other obstacles, have made it difficult for sponsors to pinpoint optimal sites.  

Real-world data (RWD) and the real-world evidence (RWE) derived from analysis of the data are a cornerstone of clinical advancements in today’s fast-paced research environment

The healthcare and clinical research industries are undergoing a seismic shift. Rapid advancements in real-world data (RWD), artificial intelligence (AI), and patient-centric approaches are rewriting the playbook for clinical trials and treatment development. The future of healthcare is here, and organizations that embrace these changes will be at the forefront of innovation. 

Clinical trials are vital to drug development but often face challenges such as slow patient recruitment, high costs, and suboptimal trial designs. Today, artificial intelligence (AI) and real-world data (RWD) are transforming this process by optimizing trial protocols, enhancing recruitment, and accelerating timelines.  

In the evolving landscape of clinical research, the era of one-size-fits-all clinical trials is firmly behind us. Regulatory bodies and industry leaders alike recognize the necessity of diverse representation in trials to ensure that medical treatments are effective for all populations.

Multiple myeloma (MM) is a rare and complex blood cancer that affects plasma cells in the bone marrow. These malignant cells accumulate and interfere with normal blood cell production, leading to complications such as anemia, kidney dysfunction, bone lesions, and increased susceptibility to infections.

The integration of digital technology is transforming clinical research, improving the efficiency of trial design and execution. A key innovation in this space is the digital waiting room, which leverages real-world data (RWD) and artificial intelligence (AI) to enhance the critical “last mile” of a trial—when sites are activated, and patient recruitment begins. 

SCOPE 2025, held from February 3-6 in Orlando, Florida, brought together over 4,500 leaders in clinical operations and research to discuss the latest advancements in clinical trial innovation, planning, management, and operations

In a rapidly evolving healthcare landscape, artificial intelligence (AI) is emerging as a transformative force in drug development and clinical research. With the average cost of bringing a new drug to market soaring to $1.3 billion and a low probability of success, the stakes for innovation have never been higher.

Adverse Drug Events (ADEs) or Adverse Drug Reactions (ADRs) continue to be a concern both in new and existing medicines. According to Medication Safety Data published by the U.S. Centers for Disease Control and Prevention (CDC), ADEs cause more than 1.5 million emergency department (ED) visits each year and nearly 500,000 patients are hospitalized after these ED visits

In the dynamic world of healthcare, real-world data (RWD) and the real-world evidence (RWE) derived from it stand as a crucial pillar for informed insights and actions.

Clinical trials are the bedrock of medical advancement, but they often grapple with a persistent challenge: ensuring diverse and representative participation. This issue isn’t just a matter of ethics—it’s crucial for delivering effective, equitable healthcare solutions.   

In an era defined by rapid advancements in technology and science, healthcare research and clinical trials are undergoing a transformative shift. At the heart of this revolution is data—vast, diverse, and ever-growing—and the collaborative efforts of stakeholders across the healthcare ecosystem.

The use of real-world evidence (RWE) in regulatory decision-making and health technology assessments (HTA) is gaining traction, particularly in the evolving landscape of oncology pharmacotherapeutics in Europe where navigating the drug approval and market access processes is becoming more complex.

In June 2024, the U.S. Food and Drug Administration (FDA) issued draft guidance outlining the need for “Diversity Action Plans” as a way for clinical trial sponsors to demonstrate their consideration toward trial representation

Cancer clinical trials have long been the cornerstone of advancements in oncology, guiding the development of new therapies and improving patient outcomes.

Pharmacoepidemiology, the study of the use and effects of drugs in large populations, has seen a significant evolution with the increasing availability of real-world data (RWD)

The landscape of clinical trials is evolving, and with it, the approach to site selection. A more patient-centric model is emerging, which flips the traditional process on its head.  

The global healthcare landscape is rapidly evolving, driven by advancements in technology, changes in regulatory frameworks, and an increased focus on patient-centered care.

Gadi Lachman, President and CEO of TriNetX, discussed the profound impact RWD is having on the healthcare industry in a Crossroads by Alantra podcast episode — Unlocking the Power of Real-World Data — released earlier this month.

“Diversity in clinical trials” is undoubtedly one of the hottest topics in the healthcare industry today and with good reason. Underrepresentation in clinical trials can have significant and wide-ranging consequences

Chronic Lymphocytic Leukemia (CLL), a type of slow-growing cancer of the blood and bone marrow, accounts for 25-30 percent of all leukemia in the Western world and is the most common type of leukemia in adults, with over 100,000 new global incidence cases and over 40,000 death cases reported globally in 2019. 

This infographic blog post is derived from the recent article by Jeffrey Brown, PhD, The Role of RWD and RWE in Shaping Global Regulatory Practices, published in the June 2024 issue of DIA Global Forum.

In the ever-evolving landscape of healthcare, collaboration isn’t just beneficial; it’s essential. TriNetX is proud to partner with our network to advance healthcare through rigorous research, innovation, and a deep dedication to improving patient outcomes. Today, we are honored to recognize the University Medical Center Schleswig-Holstein (UKSH).

Many clinical trials struggle to enroll patients, hindering meaningful results and delaying the delivery of therapies to patients. Real-world data (RWD) addresses this by overcoming barriers such as overly strict enrollment criteria and disconnects between research design and patients’ lived experiences.

Some of the most prominent and visible roles of real-world data (RWD) and real-world evidence (RWE) are regulatory and clinical decision-making and disease research. However, RWD and RWE have been growing in influence in many other areas of healthcare and in regions all over the world.

Earlier this year, the FDA rejected an application for a new cancer drug because it was based on a trial conducted in China, and the agency ruled it did not represent the U.S. population.